Chronic Sinusitis With or Without Nasal Polyps
Conditions
Brief summary
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 3-month open-label treatment phase. The duration of each subject's participation is approximately 13 weeks.
Interventions
DRUGFluticasone Propionate
Fluticasone Propionate 400 μg
Sponsors
Optinose US Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women aged 18 years and older * Women must * be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method \[eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel\], or male partner sterilization) before entry and throughout the study, or * be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or * be postmenopausal (spontaneous amenorrhea for at least 1 year). * Women of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the screening visit * Have either: a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge): 1. nasal blockage/congestion 2. nasal discharge (anterior and/or posterior nasal discharge) 3. facial pain or pressure 4. reduction or loss of smell * Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent; See Attachment 1) for at least 3 months before screening with plans to continue use throughout the study. * Must be able to cease treatment with intranasal steroids and inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit * Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at the screening visit, see Section 12.1, Visit 1, screening procedures. * Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion criteria
* Women who are pregnant or lactating * Inability to have each nasal cavity examined for any reason, including nasal septum deviation * Nasal septum perforation * Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit * Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasoendoscopy * History of sinus or nasal surgery within 6 months before the screening visit * Current, ongoing rhinitis medicamentosa (rebound rhinitis) * Have significant oral structural abnormalities, eg, a cleft palate * Diagnosis of cystic fibrosis * History of Churg-Strauss syndrome or dyskinetic ciliary syndromes * Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution * Planned sinonasal surgery during the period of the study * Allergy, hypersensitivity, or contraindication to corticosteroids or steroids * Allergy or hypersensitivity to any excipients in study drug * Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or COPD * Have nasal candidiasis * Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit; examples of these medications can be found in Section 11.6, Concomitant Medication. * History or current diagnosis of any form of glaucoma or ocular hypertension (ie, intraocular pressure \>21 mmHg) * History of intraocular pressure elevation on any form of steroid therapy * History or current diagnosis of the presence (in either eye) of a cataract * Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study * A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study * Positive urine drug screen at screening visit for drugs of abuse (see Section 14.5), with the exception of prescribed medications for legitimate medical conditions * Have participated in a previous clinical trial of OPTINOSE FLUTICASONE * Have participated in an investigational drug clinical trial within 30 days of the screening visit * Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | Baseline to 3 months or End of Study | Adverse Events were collected via spontaneous subject report and through physician examination. The display of adverse events is by subject. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| OPN-375 OPN-375 400 mcg/twice daily | 705 |
| Total | 705 |
Baseline characteristics
| Characteristic | OPN-375 |
|---|---|
| Age, Continuous | 45.3 years STANDARD_DEVIATION 13.71 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 81 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 624 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants |
| Race (NIH/OMB) Asian | 28 Participants |
| Race (NIH/OMB) Black or African American | 114 Participants |
| Race (NIH/OMB) More than one race | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 3 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 552 Participants |
| Region of Enrollment United States | 705 participants |
| Sex: Female, Male Female | 403 Participants |
| Sex: Female, Male Male | 302 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 180 / 705 |
| serious Total, serious adverse events | 5 / 705 |
Outcome results
Primary
Adverse Events
Adverse Events were collected via spontaneous subject report and through physician examination. The display of adverse events is by subject.
Time frame: Baseline to 3 months or End of Study
Population: All subject who received at least one dose of study medication
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| OPN-375 | Adverse Events | 270 participants |